Companies / Ayuvant
Ayuvant
Company
Ayuvant is developing a novel immunotherapy based on RNA-nanoparticles that instruct the immune system on how to recognise and attack cancer cells.
Ayuvant has 2 investors on file, among them AIR Capital and Draper Cygnus. Its site was last checked 7 Nov 2026: site answers.
Investors
2 investors on file| Investor | Evidence | Type |
|---|---|---|
| Portfolio page | Venture capital | |
| Portfolio page | Venture capital |
More from AIR Capital
59 companies on its checked portfolioIts portfolio leans to AI & Machine Learning (36%), Healthcare & Biotech (25%), Industrial & Manufacturing (8%).
More from Draper Cygnus
30 companies on its checked portfolioIts portfolio leans to AI & Machine Learning (35%), Space & Defense (8%), Industrial & Manufacturing (8%).
A company is shown only after its own site answers and carries its name. Sites are checked again on a schedule, because domains lapse and get bought. Round stages and dates come from Fundup AI; investor links come from portfolio pages and rounds; other facts name their source when you point at them. How we grade the data
Get Ayuvant and its investors as data
Look up any company's investors, or any investor's full portfolio, through one API key or MCP. A free account also opens Ask AI searches and alerts when AIR Capital adds a company.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/companies/ayuvant.com/investors
# also
GET /v1/companies/ayuvant.com
GET /v1/companies/ayuvant.com/news